3billion, Inc. engages in the provision of genetic testing and analyzing services to rare disease patients. The firm's products include 3B-Genome, 3B-Exome, 3B-Variant, and 3B-Interpreter. Its services include sequencing, artificial intelligence (AI) genetic mutation pathogenicity reading, full-length exome and genome analysis gene region, and proband target scope. The company was founded by Chang-Won Keum on October 10, 2016 and is headquartered in Seoul, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company